---
title: Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated
  radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)
date: '2023-12-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38116137/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231220170721&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: When considering the potential protective effect of BEV,
  which we hypothesized might reduce the risk of RN by approximately two-fold, achieving
  isotoxicity with the proposed dose-escalated experimental plan for the PRIDE trial
  seems ...'
disable_comments: true
---
CONCLUSION: When considering the potential protective effect of BEV, which we hypothesized might reduce the risk of RN by approximately two-fold, achieving isotoxicity with the proposed dose-escalated experimental plan for the PRIDE trial seems ...